Pancreatic Cancer Research

ResearcherComprehensive Cancer Center ViennaActive in the last 2 years

Gerald W. Prager

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-7854-7781; OpenAlex author ID A5034847353, A5108153474. Sources: OpenAlex.

Their work

Papers
36 (first author 4, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
90
Papers, trials and grants by year

2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: 4 papers · 2020: 4 papers · 2021: 4 papers · 2022: 1 paper · 2023: 9 papers · 2024: 3 papers · 2025: 3 papers · 2026: 4 papers

Papers 36

  1. Second-line liposomal irinotecan plus S-1 vs. liposomal irinotecan plus 5-fluorouracil in metastatic pancreatic cancer: The phase I/II randomized NAPAN trial. Co-author DOI 10.1016/j.ejca.2026.116683↗
  2. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  3. Para-aortic lymph nodes in oligometastatic pancreatic ductal adenocarcinoma - Authors' reply. First author DOI 10.1016/s1470-2045(26)00249-4↗
  4. Biomarker Analysis from Patients with Metastatic PDAC Treated with TGFβ Antibody NIS793 plus Abraxane + Gemcitabine versus Abraxane + Gemcitabine Alone in a Ph… Co-author DOI 10.1158/1078-0432.ccr-26-0805↗
  5. Long-term survival in patients with pancreatic cancer treated with second-line liposomal irinotecan plus 5-fluorouracil/leucovorin: observations from Korea, It… Last author DOI 10.1016/j.esmogo.2025.100217↗
  6. NALIRIFOX in the treatment of metastatic pancreatic ductal adenocarcinoma: an exploratory analysis of real-world data. Last author DOI 10.1016/j.esmoop.2025.105827↗
  7. Prognostic factors for very early recurrence after neoadjuvant treatment and curative resection in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2025.109647↗
  8. Prognostic significance of mean corpuscular volume in patients with pancreatic ductal adenocarcinoma and multimodal treatment. Co-author DOI 10.1016/j.jviscsurg.2023.06.004↗
  9. Immune cell distribution and DNA methylation signatures differ between tumor and stroma enriched compartment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.trsl.2024.05.005↗
  10. Prognostic Factors for Early Recurrence After Resection of Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.1053/j.gastro.2024.05.028↗
  11. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Co-author DOI 10.1016/j.annonc.2023.08.009↗
  12. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort. Co-author DOI 10.1016/j.ejca.2023.04.012↗
  13. Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer. Co-author DOI 10.1016/j.ejca.2023.113293↗
  14. Clinical risk factors for ascites in metastatic pancreatic cancer. Co-author DOI 10.1016/j.esmoop.2023.101200↗
  15. Prognosticators of survival in patients with metastatic pancreatic cancer and ascites. Co-author DOI 10.1016/j.esmoop.2023.102048↗
  16. Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus. Co-author DOI 10.1016/j.esmoop.2023.102067↗
  17. Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world stud… Co-author DOI 10.1186/s12885-023-11377-1↗
  18. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  19. Plasma Clot Properties in Patients with Pancreatic Cancer. First author DOI 10.3390/cancers15164030↗
  20. Expression of CD98hc in Pancreatic Cancer and Its Role in Cancer Cell Behavior. Co-author DOI 10.7150/jca.70500↗
  21. Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non… Co-author DOI 10.1016/j.ejca.2020.11.003↗
  22. Hemostatic Biomarkers and Venous Thromboembolism Are Associated With Mortality and Response to Chemotherapy in Patients With Pancreatic Cancer. First author DOI 10.1161/atvbaha.121.316463↗
  23. Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Sequencing. Co-author DOI 10.2147/cmar.s308029↗
  24. Chart review of diagnostic methods, baseline characteristics and symptoms for European patients with pancreatic cancer. Co-author DOI 10.2217/fon-2020-0749↗
  25. First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observa… First author DOI 10.1136/esmoopen-2019-000587↗
  26. The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc anal… Co-author DOI 10.1177/1758835919900872↗
  27. Applied precision medicine in metastatic pancreatic ductal adenocarcinoma. Last author DOI 10.1177/1758835920938611↗
  28. Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients. Last author DOI 10.3390/jcm9030648↗
  29. Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. Co-author DOI 10.1016/j.ctrv.2019.05.007↗
  30. SERPINB7 Expression Predicts Poor Pancreatic Cancer Survival Upon Gemcitabine Treatment. Last author DOI 10.1016/j.tranon.2018.08.019↗
  31. Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine. Co-author DOI 10.1177/1756284819877635↗
  32. A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid. Last author DOI 10.1177/1758835919853196↗
  33. Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chem… Last author DOI 10.1007/s12032-018-1223-3↗
  34. Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer. Last author DOI 10.1007/s12254-017-0352-2↗
  35. Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel. Last author DOI 10.1038/s41598-017-04743-0↗
  36. Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma. Co-author DOI 10.3978/j.issn.2078-6891.2015.107↗

Closest collaborators

The 25 strongest of 90 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Carl-Stephan Leonhardt · 5 shared papers, 2023–2026 · strength 1.35
  2. Oliver Strobel · 5 shared papers, 2023–2026 · strength 1.35
  3. Teresa Mercade Macarulla · 7 shared papers, 2019–2026 · strength 1.28
  4. Martin Schindl · 7 shared papers, 2016–2025 · strength 1.08
  5. Matthias Unseld · 8 shared papers, 2017–2022 · strength 0.91
  6. Markus Kieler · 8 shared papers, 2017–2022 · strength 0.91
  7. Daniela Bianconi · 8 shared papers, 2017–2022 · strength 0.91
  8. Thomas P. Hank · 3 shared papers, 2023–2025 · strength 0.62
  9. Klaus Sahora · 3 shared papers, 2023–2025 · strength 0.58
  10. Julien Taı̈eb · 4 shared papers, 2020–2023 · strength 0.57
  11. J. Thaler · 3 shared papers, 2021–2023 · strength 0.57
  12. Anna Sophie Berghoff · 3 shared papers, 2023–2024 · strength 0.53
  13. Elisabeth Sophie Bergen · 3 shared papers, 2023–2024 · strength 0.53
  14. Julia Maria Berger · 3 shared papers, 2023–2024 · strength 0.53
  15. Davide Melisi · 3 shared papers, 2020–2026 · strength 0.53
  16. Werner Scheithauer · 5 shared papers, 2016–2020 · strength 0.47
  17. Thomas Theodor Werner Seufferlein · 3 shared papers, 2019–2023 · strength 0.43
  18. Sara Lonardi · 2 shared papers, 2023–2025 · strength 0.42
  19. Christoph Benedikt Westphalen · 3 shared papers, 2020–2023 · strength 0.40
  20. Ingrid Pabinger · 2 shared papers, 2021–2023 · strength 0.39
  21. Cihan Ay · 2 shared papers, 2021–2023 · strength 0.39
  22. Carlos F. Fernandez-del Castillo · 2 shared papers, 2023–2025 · strength 0.39
  23. Andrew Louis Warshaw · 2 shared papers, 2023–2025 · strength 0.39
  24. Motaz Qadan · 2 shared papers, 2023–2025 · strength 0.39
  25. Keith D. Lillemoe · 2 shared papers, 2023–2025 · strength 0.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.